Abstract:Toll-like receptors (TLRs), as the most important pattern recognition receptors in innate immunity, play a pivotal role in inducing immune response through recognition of microbial invaders or specific agonists. Recent studies have suggested that TLRs could serve as important regulators in the development of a variety of cancer. However, increasing evidences have shown that TLRs may display quite opposite outcomes in cancer development. Although several potential therapeutic Toll-like receptor ligands have been found, the mechanism and therapy prospect of TLRs in cancer development has to be further elucidated to accelerate the clinical application. By performing a systematic review of the present findings on TLRs in cancer immunology, we attempted to evaluate the therapeutic potential of TLRs in cancer therapy and elucidate the potential mechanism of cancer progress regulated by TLR signaling and the reported targets on TLRs for clinical application. An electronic databases search was conducted in PubMed, Chinese Scientific Journal Database, and Chinese Biomedical Literature Database from their inception to February 1, 2016. The following keywords were used to search the databases: Toll-like receptors, cancer therapy, therapeutic target, innate immunity. Of 244 studies that were identified, 97 nonrelevant studies were excluded. In total, 147 full-text articles were assessed, and from these, 54 were excluded as they did not provide complete key information. Thus, 93 studies were considered eligible and included in the analysis. According to the data from the included trials, 14 TLR ligands (77.8%) from 82 studies have been demonstrated to display antitumor property in various cancers, whereas 4 ligands (22.2%) from 11 studies promote tumors. Among them, only 3 TLR ligands have been approved for cancer therapy, and 9 ligands were in clinical trials. In addition, the potential mechanism of recently reported targets on TLRs for clinical application was also evaluated in this review. We show that targeting TLRs in cancer immunotherapy is a promising strategy for cancer therapy, and the specific TLR ligands, either alone or combination, exhibit antitumor potential.

Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review)

Immunomodulation of Interleukin-34 and Its Potential Significance As a Disease Biomarker and Therapeutic Target

Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD

Death-Domain-Receptor 3 Deletion Normalizes Inflammatory Gene Expression and Prevents Ileitis in Experimental Crohn's Disease

Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics.

Role of TL1A in Inflammatory Autoimmune Diseases: A Comprehensive Review

Recent Trends in the Development of Toll-like Receptor 7/8-Targeting Therapeutics.

TNF receptors: Structure-function relationships and therapeutic targeting strategies

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Vascular Inflammation and Atherosclerosis: A Protector or Culprit?

TLR10: Insights, controversies and potential utility as a therapeutic target

Specific Nlrp3 Inflammasome Inhibitors: Promising Therapeutic Agents For Inflammatory Diseases

TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity

Application potential of toll-like receptors in cancer immunotherapy: Systematic review.

TLR Signaling Pathways: Opportunities for Activation and Blockade in Pursuit of Therapy

Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review)

Application and Prospect of Targeting Innate Immune Sensors in the Treatment of Autoimmune Diseases

From Molecular Mechanisms to Clinical Applications

A review: Mechanisms and molecular pathways of signaling lymphocytic activation molecule family 3 (SLAMF3) in immune modulation and therapeutic prospects

Tumor necrosis factor-like cytokine 1A plays a role in inflammatory bowel disease pathogenesis

Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells

Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections.